Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diuretics in Early CKD (DOCK)
NCT04192110Phase 4Withdrawn
- Sponsor
- VA Office of Research & Development
- Start
- Aug 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hydrochlorothiazide, chlorthalidone, furosemide, bumetanide and torasemide in chronic kidney disease (CKD) and hypertension (HTN), sponsored by VA Office of Research & Development. Primary endpoints: N-terminal pro-brain natriuretic peptide at 4 weeks and Total Peripheral Resistance Index at 4 weeks. Planned start Aug 2020; status: withdrawn.
02
Drugs
hydrochlorothiazidechlorthalidonefurosemidebumetanidetorasemide
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on NCT04192110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04192110.